Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.

Conley GP, Viswanathan M, Hou Y, Rank DL, Lindberg AP, Cramer SM, Ladner RC, Nixon AE, Chen J.

Biotechnol Bioeng. 2011 Nov;108(11):2634-44. doi: 10.1002/bit.23220. Epub 2011 Jun 13.

PMID:
21618474
2.

Aggregates in monoclonal antibody manufacturing processes.

Vázquez-Rey M, Lang DA.

Biotechnol Bioeng. 2011 Jul;108(7):1494-508. doi: 10.1002/bit.23155. Epub 2011 Apr 20. Review.

PMID:
21480193
3.

Using partition designs to enhance purification process understanding.

Pieracci J, Perry L, Conley L.

Biotechnol Bioeng. 2010 Dec 1;107(5):814-24. doi: 10.1002/bit.22866.

PMID:
20632374
4.

Toward aggregation-resistant antibodies by design.

Lee CC, Perchiacca JM, Tessier PM.

Trends Biotechnol. 2013 Nov;31(11):612-20. doi: 10.1016/j.tibtech.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23932102
5.

Structure-based engineering of a monoclonal antibody for improved solubility.

Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y.

Protein Eng Des Sel. 2010 Aug;23(8):643-51. doi: 10.1093/protein/gzq037. Epub 2010 Jun 11.

PMID:
20543007
6.

Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain.

Pybus LP, James DC, Dean G, Slidel T, Hardman C, Smith A, Daramola O, Field R.

Biotechnol Prog. 2014 Jan-Feb;30(1):188-97. doi: 10.1002/btpr.1839. Epub 2013 Dec 6.

PMID:
24311306
7.

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

Wu H, Nie Y, Huse WD, Watkins JD.

J Mol Biol. 1999 Nov 19;294(1):151-62.

PMID:
10556035
8.

Natural and designer binding sites made by phage display technology.

Hoogenboom HR, Chames P.

Immunol Today. 2000 Aug;21(8):371-8. Review.

PMID:
10916139
9.

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.

Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ.

Trends Biotechnol. 2013 Nov;31(11):621-32. doi: 10.1016/j.tibtech.2013.08.007. Epub 2013 Oct 2. Review.

PMID:
24094861
10.

Antibody engineering and modification technologies.

Filpula D.

Biomol Eng. 2007 Jun;24(2):201-15. Epub 2007 Mar 31. Review.

PMID:
17466589
11.

Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E.

Protein Sci. 2010 May;19(5):954-66. doi: 10.1002/pro.372.

12.

Guidelines to cell engineering for monoclonal antibody production.

Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R.

Eur J Pharm Biopharm. 2010 Feb;74(2):127-38. doi: 10.1016/j.ejpb.2009.10.002. Epub 2009 Oct 22. Review.

PMID:
19853660
13.

Optimization of Fc-mediated effector functions of monoclonal antibodies.

Strohl WR.

Curr Opin Biotechnol. 2009 Dec;20(6):685-91. doi: 10.1016/j.copbio.2009.10.011. Epub 2009 Nov 4. Review.

PMID:
19896358
14.

Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF.

Wang S, Liu M, Zeng D, Qiu W, Ma P, Yu Y, Chang H, Sun Z.

Proteins. 2014 Oct;82(10):2620-30. doi: 10.1002/prot.24626. Epub 2014 Jul 5.

PMID:
24916692
15.

Engineering fully human monoclonal antibodies from murine variable regions.

Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA.

J Mol Biol. 2010 Mar 12;396(5):1474-90. doi: 10.1016/j.jmb.2009.12.046. Epub 2010 Jan 4.

PMID:
20045416
16.
17.

Rational and systematic protein purification process development: the next generation.

Nfor BK, Verhaert PD, van der Wielen LA, Hubbuch J, Ottens M.

Trends Biotechnol. 2009 Dec;27(12):673-9. doi: 10.1016/j.tibtech.2009.09.002. Epub 2009 Oct 6.

PMID:
19815300
18.

Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.

den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W.

Pharm Res. 2011 Apr;28(4):920-33. doi: 10.1007/s11095-010-0297-1. Epub 2010 Oct 23.

19.

Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.

Tanha J, Nguyen TD, Ng A, Ryan S, Ni F, Mackenzie R.

Protein Eng Des Sel. 2006 Nov;19(11):503-9. Epub 2006 Sep 13.

PMID:
16971398
20.

Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.

Wang X, Campoli M, Ko E, Luo W, Ferrone S.

J Immunol Methods. 2004 Nov;294(1-2):23-35.

PMID:
15604013

Supplemental Content

Support Center